Company news

INmune Bio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 30, 2025

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

June 30, 2025

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 27, 2025

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

June 26, 2025

XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense

June 10, 2025

INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 8, 2025

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

May 5, 2025

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

April 16, 2025

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

April 14, 2025

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

April 1, 2025

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

March 27, 2025

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

March 24, 2025

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

February 11, 2025

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

February 9, 2025

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

January 27, 2025

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

December 9, 2024

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

December 3, 2024

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

November 12, 2024

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

October 30, 2024

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

October 27, 2024

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

October 23, 2024

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

October 23, 2024

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

October 10, 2024

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

September 29, 2024

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

September 25, 2024

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

September 16, 2024

INmune Bio Announces $13.0 Million Registered Direct Offering

September 12, 2024

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

September 2, 2024

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

July 31, 2024

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

July 28, 2024

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

July 24, 2024

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

July 22, 2024

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

June 26, 2024

INmune Bio Inc. to Join Russell 3000® Index

May 29, 2024

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

May 8, 2024

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

May 6, 2024

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

April 29, 2024

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

April 28, 2024

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 24, 2024

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

April 22, 2024

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

April 21, 2024

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

April 7, 2024

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

March 27, 2024

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

March 25, 2024

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

March 12, 2024

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

March 4, 2024

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 11, 2024

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

February 5, 2024

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

January 29, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.